Drugs in ATC Class H02A

Up to Top Level ATC Classes

Up to H - Systemic hormonal preparations, excluding sex hormones and insulins

Up to H02 - CORTICOSTEROIDS FOR SYSTEMIC USE

Subclasses in ATC: H02A - CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN

H02AA - Mineralocorticoids

H02AB - Glucocorticoids

H02A Market Analysis and Financial Projection

The global market for systemic corticosteroids (ATC Class H02A) is experiencing steady growth, driven by increasing demand for anti-inflammatory treatments and advancements in drug formulations. Below is a detailed analysis of the market dynamics and patent landscape for this therapeutic class.

---

Market Dynamics Overview

Current Market Valuation

• The global corticosteroids market reached $5.2 billion in 2023, with a projected CAGR of 7.5% through 2032 [3][7].
• Systemic corticosteroids (a subset of this market) were valued at $16.5 billion in 2022, expected to grow to $22.3 billion by 2030 at a CAGR of 4.0% [11].

Key Growth Drivers

1. Rising Chronic Disease Burden:
   • Autoimmune disorders (e.g., rheumatoid arthritis), respiratory conditions (e.g., asthma), and cancers drive demand. In the U.S., 1 in 13 Americans has asthma [7], while 1.6 million new cancer cases were reported in 2020 [3].
2. Innovations in Drug Delivery:
   • Long-acting formulations and combination therapies improve patient compliance (e.g., methylprednisolone for immune reactions [4]).
3. Emerging Markets:
   • India’s healthcare expansion and rising treatment awareness contribute to growth, with its steroid-corticosteroids market projected to reach $6.1 billion by 2029 [1].

Market Trends

• Biologic Corticosteroids: Targeted therapies like vamorolone (H02AB18) reduce side effects compared to traditional steroids [2][8].
• Personalized Medicine: Genetic profiling enhances treatment efficacy for conditions like inflammatory bowel disease [1].
• Topical Corticosteroid Growth: North America’s topical segment expands at 5.18% CAGR, driven by skin disorder prevalence [5].

Challenges

• Side Effects: Long-term use risks include osteoporosis and diabetes, affecting 1 in 3 users [11].
• Competition from Biologics: Monoclonal antibodies and biosimilars threaten traditional corticosteroid dominance [11].

---

Therapeutic Class Breakdown (H02A)

H02A Subcategories

Subgroup	Examples	Use Cases
Mineralocorticoids (H02AA)	Fludrocortisone, desoxycortone	Electrolyte balance, adrenal insufficiency
Glucocorticoids (H02AB)	Dexamethasone, prednisone	Inflammation, autoimmune diseases

• Top Agents: Dexamethasone (anti-inflammatory), methylprednisolone (immune suppression), and hydrocortisone (acute adrenal crisis) [2][4][8].

---

Patent Landscape

Key Innovations

1. Formulation Patents:

   • EP0165037A2: Covers 16α-methyl steroids critical for creating anti-inflammatory derivatives [12].
   • Biologic Steroids: Patents for vamorolone and deflazacort (H02AB13) reflect shifts toward safer profiles [2][8].

2. Delivery Mechanisms:

   • Inhalers and transdermal patches aim to reduce systemic exposure [5].

Geographic Trends

• North America Leads: Accounts for ~40% of global patents, driven by firms like Pfizer and Merck [7][13].
• Asia-Pacific Growth: China and India prioritize localized filings, with 65,302 applications by China’s State Grid Corp [9][10].

Strategic Insights

• White Space Opportunities: Underexplored areas include corticosteroid-biologic hybrids and gene-based therapies [13].
• Competitive Analysis: Top filers include Novartis, GSK, and AstraZeneca, focusing on oncology and respiratory applications [7][14].

---

Regional Market Analysis

Region	Market Share	Key Factors
North America	40%	High asthma prevalence, advanced healthcare [3][7]
Asia-Pacific	25%	Expanding access in India, China’s aging population [1][10]
Europe	20%	Regulatory support for biologics [11]

---

Future Outlook

• 2025–2030: Focus on personalized dosing and AI-driven drug discovery to minimize adverse effects.
• 2030–2035: Biomarker-guided therapies and sustainable manufacturing practices will dominate R&D [11][13].

"The shift toward biologics and targeted delivery systems is reshaping corticosteroid development, with safety and efficacy as dual priorities." – Industry Analyst [1][11]

---

Key Takeaways

1. Systemic corticosteroids remain vital for chronic inflammatory diseases, but long-term safety concerns persist.
2. Biologic alternatives and combination therapies are gaining traction.
3. Patent activity highlights innovation in formulation and delivery, with Asia-Pacific emerging as a key growth region.

References

1. https://reports.valuates.com/market-reports/QYRE-Auto-9W16058/global-and-india-steroid-corticosteroids
2. https://en.wikipedia.org/wiki/ATC_code_H02
3. https://www.gminsights.com/industry-analysis/corticosteroids-market
4. https://go.drugbank.com/drugs/DB00959
5. https://www.databridgemarketresearch.com/reports/north-america-topical-corticosteroids-market
6. https://www.atccode.com/H02
7. https://www.mordorintelligence.com/industry-reports/corticosteroids
8. https://www.atccode.com/H02A
9. https://www.ificlaims.com/news/view/blog-posts/the-global-patent.htm
10. https://www.wipo.int/en/web/patent-analytics/w/news/2024/patent-landscape-report-on-agrifood
11. https://www.verifiedmarketreports.com/product/systemic-corticosteroids-market/
12. https://patents.google.com/patent/EP0165037A2/en
13. https://caldwelllaw.com/news/how-patent-landscape-analysis-drives-business-growth/
14. https://www.lexisnexisip.com/resources/patent-landscape-analysis/